Our studies with human breast cancer cells suggest that ERLIN2 does not function as a mediator of ERAD although it interacts with the ER-resident insulin-induced gene 1 protein (INSIG1) to regulate activation of sterol regulatory element-binding protein (SREBP) 1c, the key regulator of de novo lipogenesis [13]. Here, ERLIN2 is linked to breast cancer.